SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as a Bitcoin-native meme coin launched via the Runes protocol, generating buzz for its fair distribution and strong community. Discussions highlight its potential to drive utility and transaction volume on the Bitcoin network, with many touting it as a leader in the current cycle. Community members are actively promoting its unique position compared to other meme coins and speculating about potential exchange listings.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is trending due to its strong community and growing holder count, signaling increasing interest and conviction. The community is actively discussing the potential for a major rally, driven by the expectation of a significant move in the dawg coin sector. Many believe $KENDU.X is undervalued and primed for substantial growth, emphasizing its real-world applications and brand development.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending due to positive updated Phase 3 HARMONi data for its lung cancer drug, ivonescimab, sparking optimism about its potential. The community is focused on the drug's OS benefit and its competitive efficacy compared to existing treatments, while also debating the validity and interpretation of trial data. Some investors are speculating about a potential acquisition or partnership, particularly with AstraZeneca, driving further interest in the stock.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community discusses potential catalysts, including speculation around a Dogecoin ETF and its impact on price. Sentiment is focused on the potential for significant gains, with some looking toward the token reaching the $1 mark. The conversation also includes discussion around Dogecoin's relationship with other meme coins and their respective ecosystems.

DOVU

DOVU.X is trending as the community highlights its staking rewards and potential in the Real World Asset (RWA) space, particularly due to its "Trust Operating System." Recent news around partnerships and deals related to carbon credits and ecological projects may be acting as a catalyst. Community members are actively discussing its association with Hedera and potential for significant growth.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to a significant land sale agreement, potentially boosting its NAV. The community is discussing the stock's low float and potential for a substantial price increase, with some highlighting potential squeeze dynamics. Bullish sentiment appears to be building, driven by the company's real estate assets and upcoming shareholder meeting.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

$DOG is trending as the Bitcoin memecoin gains traction within the crypto community, with many touting its fair launch and strong community backing. Conversation highlights its potential to become the meme face of Bitcoin and draw comparisons to other popular memecoins. Community members are emphasizing its organic growth and decentralized nature.

The Children's Place, Inc. engages in the provision of apparel, footwear, accessories, and other items for children. The firm also designs contracts to manufacture and sell fashionable and value-priced merchandise under the brand names of The Children’s Place, Baby Place, and Gymboree. It operates through The Children’s Place U.S. and The Children’s Place International segments. The Children’s Place U.S. segment refers to the company’s U.S. and Puerto Rico-based stores and revenue from its U.S. based wholesale business. The Children’s Place International segment is involved in the Canadian-based stores, revenue from the company’s Canadian-based wholesale business, as well as revenue from international franchisees. The company was founded by David Pulver and Clinton A. Clark in 1969 and is headquartered in Secaucus, NJ.

Childrens Place Inc

Children's Place is trending due to recent earnings and guidance, with discussions centered on a potential short squeeze given its high short interest. Community members are debating the company's turnaround efforts and the impact of new management, with some highlighting positive comparable DTC sales and others expressing concerns about financials and potential bankruptcy. The stock's low float and high short interest are fueling speculation about a significant price movement.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense is trending as community members discuss its potential involvement in upcoming military programs and the recent partnership with Airbus for European markets. Bullish sentiment is fueled by the company's positioning in the defense sector, particularly related to drone technology and hypersonic systems. Some investors are speculating about future contracts and a potential stock split, while others are noting technical indicators and potential resistance levels.

K9 Finance, a Shibarium-based LSD platform, offers core DeFi services and acts as an official validator. Rewarding $KNINE holders with $BONE for block validation, it aims to drive DeFi adoption via the 'Roundtable of Dogs' DAO, which governs treasury and roadmap decisions.

K9 Finance DAO

K9 Finance DAO ($KNINE.X) is trending due to the upcoming K9 Quest Airdrop and its role as a key player in Shibarium's DeFi ecosystem, offering liquid staking for $BONE.X. The community is actively discussing staking strategies, DAO governance, and ways to earn rewards through Bonecrusher and ShibaSwap integration. With its innovative tri-token system and focus on real yield, K9 Finance is positioned to drive DeFi adoption on Shibarium.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business...

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services Citius Pharmaceuticals and Citius Oncology Announce Unique...

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch...

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives...

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update...

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides...

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients with Recurrent Solid Tumors

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer...

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment...

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology...

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and...

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Current Price	$1.88
Prev Close	$1.87
Open	$1.80
Dividend Yield	0.00%
50-Day Moving Average	$2.39
Beta	-2.47
Avg. Volume	253,952.29
PE Ratio	-9.87

52-Week High	$6.19
52-Week Low	$0.5506
Market Capitalization	$147.34M
EPS (Annual)	-$0.3108
Price to Book	4.15
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

CTOR
Citius Oncology Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest CTOR News

CTOR Citius Oncology Inc.